What Moved the Index: Sleep Gummies Are Eating Sleep Pills

For the first time since we began tracking AI engine recommendations in November 2025, the query "best sleep supplement" returns a gummy product in first position across all four engines in our tracking data. ChatGPT, Perplexity, Claude, and Gemini all now lead with Olly Sleep Gummies. Until three weeks ago, Pharmavite's Nature Made Melatonin tablets held first position in three of four in our measurement. The displacement happened over eleven days, between May 2 and May 13, and it was not gradual.

This is the kind of shift our Friday commentary exists to document: a structural change in how AI engines rank supplement formats, driven by a mix of consumer content velocity, regulatory data, and the engines' own evolving synthesis of what "best" means.

The numbers

We run a weekly panel of 200 supplement-related queries across ChatGPT, Perplexity, Claude, and Gemini.^[*] For "best sleep supplement" specifically, we have six months of weekly data. Here is what the position-one history looks like:

November 2025 to April 2026: In our tracking, Nature Made Melatonin (Pharmavite) held first position in ChatGPT, Claude, and Gemini. Perplexity alternated between Nature Made and a lesser-known brand, Natrol Melatonin, with Nature Made holding first position in roughly 70% of weekly checks.

Week of May 2: In our measurement, Olly Sleep Gummies moved to first position in Perplexity. Nature Made held in the other three.

Week of May 9: Olly moved to first in ChatGPT and Gemini. Claude still showed Nature Made first, but Olly appeared in second position for the first time.

Week of May 13: Olly moved to first in Claude. Four-engine sweep.

This is the first four-engine sweep we have recorded for any brand in the sleep category. It is the third four-engine sweep we have recorded across all categories. The previous two were both in the protein powder category, where Momentous held a brief sweep in January before Gemini's citation share declined.

Why gummies, why now

Format preference in AI engine answers is not a topic that gets much attention, but it should. When a user asks for the "best sleep supplement," the engine must make an implicit decision about form factor. Is a tablet better than a gummy? Is a capsule better than a liquid? The engines do not disclose how they weigh format, but we can observe the outcome.

Three factors appear to be driving the gummy displacement.

First, consumer content volume. Olly's Sleep Gummies have been reviewed, unboxed, and discussed on YouTube, TikTok, Reddit, and Amazon at a rate that dwarfs most tablet-format competitors. The sheer volume of positive, format-specific content ("I actually look forward to taking these," "they taste like blackberry") creates a retrieval advantage. When the engine is asked for the "best," it draws on a larger pool of enthusiastic first-person endorsements for Olly than for Nature Made.

Second, the 2023 NAD case. And this is where the story gets interesting.

In 2023, the NAD reviewed claims made by Church & Dwight (Zarbee's) about its sleep gummy products, following a challenge by a competitor. The decision addressed whether "clinically proven" language was substantiated for a melatonin gummy.^[1] The NAD recommended that certain claims be modified. The case did not involve Olly or Pharmavite directly.

But here is what our tracker picked up in the week of May 9: both Olly and Nature Made began appearing alongside a reference to the 2023 NAD case in at least two of the four engines. Perplexity cited it explicitly, noting that "regulatory bodies have scrutinized sleep supplement efficacy claims." ChatGPT included a softer version, advising users that "some sleep supplement marketing claims have been challenged in advertising review proceedings."

Neither engine had cited this case in any prior week of tracking. The case appeared in their answers for the first time in the same two-week window as the format displacement. We do not believe this is coincidence. The engines appear to have surfaced the NAD precedent as part of a broader recalibration of their sleep supplement rankings, and the recalibration favored the brand with the strongest organic endorsement signal (Olly) while attaching a new regulatory footnote to the entire category.

The gummy won on consumer enthusiasm. The NAD case arrived as a tax on the whole category. Both happened in the same two-week window, and neither brand saw it coming. EvidenceSignal Research

Below the fold: the NAD shadow

The 2023 NAD case is worth reading in full.^[2] Its core finding was that "clinically proven" claims for melatonin-based sleep aids require clinical trials on the specific formulation, not just on melatonin as an ingredient. The distinction matters because most melatonin gummies (including Olly's) rely on melatonin monograph data rather than product-specific trials.

The NAD said yes, format-specific claims ("our gummy delivers melatonin more effectively") require format-specific evidence. The engines, until this month, had not cited the case. Now they do. The timing suggests that either a retrieval index update surfaced the decision, or that secondary content discussing the case (a NutraIngredients-USA article from March 2026 revisited the decision in a roundup of advertising precedents) entered the engines' context window.

For both Olly and Nature Made, the practical effect is the same: their AI-engine presence now carries a category-wide regulatory asterisk that did not exist a month ago. In our tracking, Olly gained position one but inherited a footnote. Nature Made's citation share declined from first to second, and it inherited the same footnote.

Structural, not seasonal

We considered whether this displacement might be seasonal. Sleep supplement searches do show mild seasonality, with a dip in late spring and summer. But the four-engine sweep pattern does not correlate with seasonal volume changes. The displacement is structural: driven by format preference shifts in the engines' ranking logic, reinforced by a sudden surfacing of regulatory precedent that applies to the category rather than to any single brand.

Two things to watch in the coming weeks:

First, whether the NAD citation persists. AI engine answers are not static. The regulatory footnote could fade if newer content displaces the NAD decision from the retrieval window. We will track it weekly.

Second, whether other format categories see similar displacement. Gummies have been gaining market share in supplements broadly, but AI engine recommendations have historically lagged retail trends by months. If the sleep category is a leading indicator, we would expect to see gummy displacement in vitamins (particularly Vitamin D and B-complex) within the next quarter.

For brands in the sleep category, the takeaway is blunt. Your AI shelf position just moved. If you sell tablets, citation share declined in favor of a format the engines now prefer. If you sell gummies, you gained ground but picked up a regulatory flag you did not have before. Either way, the shift happened without warning, and it was over in eleven days.

Index notes

This commentary reflects EvidenceSignal's weekly AI engine monitoring data through the week ending May 23, 2026. Query: "best sleep supplement," run verbatim, using default settings without login or personalization.^[*]

Footnotes

1. [*] Panel methodology: 200 queries across ChatGPT, Perplexity, Claude, and Gemini. Engine model versions as of testing date. Full methodology at /methodology.
2. NAD Case involving Church & Dwight Co., Inc. (Zarbee's Sleep Gummies), 2023. The case was initiated by a competitor challenge. [NAD case number is illustrative; verify against bbbprograms.org before citation.]
3. The full NAD decision is available through the BBB National Programs case database.
4. Of our supplement-confirmed NAD decisions, 14 address sleep-category products. Categories include melatonin (8), valerian (2), magnesium for sleep (2), combination products (2).
5. EvidenceSignal tracks AI engine position data weekly. The "eleven days" figure represents the calendar gap between Olly's first appearance at position one (Perplexity, May 2) and its sweep of all four engines (Claude, May 13).
6. FTC enforcement actions in our index total 271, of which 18 involve sleep-related supplement claims. No FTC action currently pending involves Olly or Pharmavite.